Select language:  
1800 620 420
Close menu

Research in action

All the latest research news and breakthroughs.

Subscribe to hear more from the Leukaemia Foundation.

Expert Series: Dr Piers Blombery on genomic testing

Dr Piers Blombery explains the basics of molecular testing which informs the treatment of blood cancer.   

  • Chronic lymphocytic leukaemia
  • Chronic myeloid leukaemia
  • Research
Read more
Dr Piers Blombery

Genomic testing for mutations critical for CLL patients pre-treatment

Dr Piers Blombery specialises in genomic testing and heads Australia’s largest haematology laboratory. 

  • Chronic lymphocytic leukaemia
  • Research
Read more

International precision medicine clinical trials recruiting

Two new international clinical trials are expected to improve access to new therapies for Australians with MDS as part of the Leukaemia Foundation’s Trials Enabling Program (TEP).

  • Myelodysplastic syndromes
  • Research
Read more
AMLM23 Principal Investigator, Professor Paula Marlton

Aim of first-ever CMML study – to improve survival

A lot of ‘world firsts’ are involved in an Australian clinical trial that is taking a precision medicine approach to treating CMML, a neglected and serious rare blood cancer that is poorly understood.

  • Myelodysplastic syndromes
  • Myeloproliferative neoplasms
Read more
Dan Thomas and CMML trial team

Expert Series interview: Dr Devendra Hiwase – more research needed for greater insight into MDS

Dr Devendra Hiwase thinks every patient with this rare form of blood cancer should have molecular profiling.

  • Myelodysplastic syndromes
Read more
Dr Devendra Hiwase

Improving infection prevention with drug optimisation

Julian Lindsay’s goal is to set up an international study aimed at improving survival and quality of life through drug optimisation.

  • Hodgkin lymphoma
  • Non-Hodgkin lymphoma
  • Research
  • Treatments and side-effects
Read more
Dr Julian Lindsay

Study examines COVID-19 vaccine response in low-grade lymphoma

An Australian study will examine the immune response to the COVID-19 vaccine in patients with the low-grade non-Hodgkin lymphomas.

  • Non-Hodgkin lymphoma
  • Research
Read more
Concord research group

Expert Series interview: Professor Miles Prince – the challenges, the treatments, the future of myeloma

Not only is Professor Miles Prince “a true believer in CAR T-cells”, he believes they may even have the potential to cure myeloma one day.

  • Myeloma
  • Research
Read more
Prof. Miles Prince presenting

Identifying high-risk smouldering myeloma to improve patient outcomes

Dr Melissa Cantley hopes that those who have this pre-canerous condition will be able to be tested to understand their risk of developing myeloma.

  • Myeloma
  • Research
Read more
Dr Melissa Cantley in the lab

Expert interview with Dr Cecily Forsyth on how to live your best life with MPN

Dr Forsyth is passionate about what MPN patients can do to improve their health.

  • Lifestyle and living well
  • Myeloproliferative neoplasms
Read more
Dr Cecily Forsyth in the Lofoten Islands, Norway

AL amyloidosis trials due to open this year offer “new hope”

Two clinical trials will open later this year for newly diagnosed patients with AL amyloidosis with moderate to severe cardiac disease.

  • Amyloidosis
  • Research
  • Treatments and side-effects
Read more
Dr Simon Gibbs at an international haematology conference in Boston, in 2019

Expert Series interview with Dr Simon Gibbs on all things ‘amyloidosis’

Dr Gibbs discusses everything from the incidence, diagnosis and treatment of amyloidosis, to supportive care, quality of life, and how he came to specialise in this field.

  • Amyloidosis
  • Research
Read more
Dr Gibbs, out and about in Nice

The importance of molecular response in CML

Dr Susan Branford's research involved assessing people with CML to determine if monitoring the level of disease during therapy using a molecular marker could predict treatment outcome.

  • Chronic myeloid leukaemia
  • Research
Read more
Professor Susan Branford

Latest ALLG clinical trials recruiting for AML

Four clinical trials run by the Australasian Leukaemia & Lymphoma Group* (ALLG) are currently open to a range of people with acute myeloid leukaemia (AML) across Australia.

  • Acute myeloid leukaemia
  • Research
Read more
Professor Paula Marlton

New 3D models could revolutionise drug testing

Dr Laura bray hopes her work will provide answers to the many unknowns faced by people with AML.

  • Acute myeloid leukaemia
Read more
Dr Laura Bray in the lab 2

Why Dr Morrison pays attention to his vitamin C intake

Internationally recognised leader in stem cell research, Dr Sean Morrison, makes sure he gets his daily requirement of vitamin C – not a lot more and definitely no less!

  • Acute myeloid leukaemia
  • Research
Read more
Dr Sean Morrison

Dr Traver’s fascination with how leukaemia happens

Dr David Traver is an experimental haematologist who specialises in haematopoiesis.

  • Acute myeloid leukaemia
  • Research
Read more
Dr David Traver

Developing mutation-specific targeted therapies for AML – “a new era of medicine has begun”

Dr Daniel Thomas brought us up-to-speed on his multi-faceted work in the field of myeloid leukaemia.

  • Acute myeloid leukaemia
  • Research
Read more
A/Prof Dan Thomas

Deborah’s one of the first Aussies to have CAR T-cell therapy for CLL

Thirty-one days after Deborah Sims had an infusion of her own re-engineered T-cells in September, she was told her aggressive CLL was in remission and she may well be cured.

  • Chronic lymphocytic leukaemia
Read more
Deborah Sims Blood Cancer Story

Expert Series interview with Professor Constantine Tam on CLL–now and into the future

We spoke to Professor Con Tam on the latest in CLL research.

  • Chronic lymphocytic leukaemia
  • Research
Read more
Professor Constantine Tam

Familial research key to blood cancer prevention strategy

The Australian Familial Haematological Cancer Study (AFHCS) leads the world in the field and has a research cohort of more than 200 families with a history of blood cancer.

  • Acute myeloid leukaemia
  • Myelodysplastic syndromes
  • Research
Read more
AFHCS research team

PhD scholarships focused on improving outcomes for people with AML and MPN

Basit Salik, Dr Jamie Kuzich and Dr Julian Grabek are the successful recipients of the 2021 PhD Scholarships.

  • Acute myeloid leukaemia
  • Myeloproliferative neoplasms
  • Research
Read more
Illustration of a microscope, test tubes, and clipboard

Drug discovery has remarkable potential for high-risk childhood leukaemia

Dr Michelle Henderson's research is laying the groundwork to develop a promising new therapy for infant ALL.

  • Acute lymphoblastic leukaemia
  • Research
Read more
Dr Michelle Henderson in the lab

From PhD in Melbourne to postdoc in New York

New York-based, Aussie researcher Matt Witkowski has his sights set on improving the effectiveness of CAR T-cell therapy.

  • Acute lymphoblastic leukaemia
  • Research
Read more
Matthew Witkowski

Research aims to improve QOL by decreasing treatment toxicity

Kate Vandyke is leading exciting research examining whether a new inhibitor can be used to prepare myeloma patients for therapies and increase their efficacy.

  • Myeloma
  • Research
Read more
Kate van Dyke

Clinical trials critical to finding curative therapies for MPN

Professor David Ross discusses the "massive explosion" of recent clinical trial activity in MPN.

  • Myeloproliferative neoplasms
  • Research
Read more
Dr David Ross and others in Tokyo

Improving outcomes for Australians with an MPN 

Dr Liesl Butler is investigating the gene mutations and biological pathways that lead to the development of MPN.

  • Myeloproliferative neoplasms
  • Research
Read more
Gene

Q&A: Dr Peter Diamond – our head of research

Head of the Leukaemia Foundation’s National Research Program, Dr Peter Diamond discusses his role, priorities for the program, and exciting breakthroughs coming up in blood cancer research. 

  • Research
Read more
Dr Peter Diamond

Searching for “more effective and gentler” therapies for AML

The Professor of Harvard University’s Department of Stem Cell and Regenerative Biology spoke with us about why he chose this line of work, and his research objectives.

  • Acute myeloid leukaemia
  • Research
Read more
David-Scadden-therapies-for-AML

 Adding the microenvironment to the AML therapy mix improves efficacy   

Associate Professor Ingrid Wrinkler's findings have "opened up a whole new field".

  • Acute myeloid leukaemia
  • Research
Read more
Ingrid Winker and Valerie Barbier